TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
Dr Andrew Goldsborough will be presenting "TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines" at 15:45 on 12th June 2025
Join us at the World Vaccine Congress next week as we showcase our latest breakthrough in mRNA-LNP stability, TheraPHIX™! We’re thrilled that our CEO, Andrew Goldsborough will be speaking on 31st October at 10am in Theatre 6. His talk, *"TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines"* will delve into how we’re reshaping the future of vaccine delivery and therapeutic stability.
We are delighted to announce our sponsorship
We are delighted to attend the 2nd Annual mRNA-Based Therapeutics Summit 24th-26th January 2023 in Berlin. Following the successful development of vaccines against Covid-19, biopharma hopes to deploy mRNA-based therapies to combat many other diseases in oncology, rare disorders, and beyond. The meeting is an ideal opportunity for us to meet colleagues from across the entire mRNA spectrum.
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com